Study 301

E125384

Study 301 is a pivotal clinical trial evaluating the efficacy and safety of the Alzheimer’s disease drug Leqembi (lecanemab) in patients with early-stage disease.

All labels observed (1)

Label Occurrences
Study 301 canonical 1

How this entity was disambiguated

Statements (13)

Predicate Object
instanceOf clinical trial ⓘ
phase 3 trial ⓘ
pivotal trial ⓘ
assesses efficacy ⓘ
safety ⓘ
diseaseStage early-stage Alzheimer’s disease ⓘ
evaluatesDrug Leqembi ⓘ
lecanemab ⓘ
linked to: Leqembi
indication Alzheimer’s disease ⓘ
linked to: Alzheimer's disease
sponsorDrugBrand Leqembi ⓘ
sponsorDrugGeneric lecanemab ⓘ
linked to: Leqembi
targetPopulation patients with early-stage Alzheimer’s disease ⓘ
therapeuticClass anti-amyloid monoclonal antibody ⓘ

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Leqembi → hasKeyClinicalTrial → Study 301 ⓘ